Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lyell Immunopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
LYEL
Nasdaq
8731
https://lyell.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lyell Immunopharma Inc
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returns
- Mar 17th, 2024 1:47 pm
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
- Mar 7th, 2024 5:00 pm
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
- Mar 5th, 2024 9:30 pm
Lyell Immunopharma Inc (LYEL) Reports 2023 Financial Results and Business Highlights
- Feb 28th, 2024 9:44 pm
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
- Feb 28th, 2024 9:05 pm
Lyell Immunopharma Announces Participation in March Investor Conferences
- Feb 26th, 2024 9:05 pm
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
- Jan 29th, 2024 2:08 pm
Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?
- Jan 4th, 2024 2:04 pm
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 9:05 pm
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
- Dec 19th, 2023 1:56 pm
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
- Nov 9th, 2023 9:05 pm
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
- Nov 7th, 2023 9:05 pm
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
- Oct 31st, 2023 1:00 pm
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 49% stake
- Oct 9th, 2023 11:32 am
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Sep 27th, 2023 1:00 pm
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform
- Sep 11th, 2023 12:00 pm
Lyell Immunopharma to Participate in Upcoming Investor Conferences
- Aug 31st, 2023 8:05 pm
Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher
- Aug 29th, 2023 10:03 am
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
- Aug 8th, 2023 8:05 pm
Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans
- Jul 12th, 2023 12:47 pm
Scroll